Pardes Biosciences, Inc.
Pardes Biosciences, Inc. (PRDS) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · PRDS · as of Sep 30, 2023
Ownership Breakdown
1
Institutional Holders
▼ 58 vs Q2
$66,730
Total Inst. Value
▼ $63.84M vs Q2
62.01M
Shares Outstanding
freeFloat 22.67%
31,037
13F Shares Held
▼ 35.28M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
PRDS largest shareholders · institutional ownership
Q3 2023 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BARCLAYS PLC pharmaceutical preparations | 31.0K | 5.15% | 5.15% | $66.73M | Mar 26, 2026 | ▼ 374.8K |
BANK OF AMERICA CORP /DE/ pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 14, 2023 | EXIT |
WELLS FARGO & COMPANY/MN pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 13, 2023 | EXIT |
NORTHERN TRUST CORP pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 13, 2023 | EXIT |
STATE STREET CORP pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 14, 2023 | EXIT |
VANGUARD GROUP INC pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Dec 18, 2023 | EXIT |
COWEN AND COMPANY, LLC pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 9, 2023 | EXIT |
FMR LLC pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 13, 2023 | EXIT |
SVB FINANCIAL GROUP pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 14, 2023 | EXIT |
JPMORGAN CHASE & CO pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 14, 2023 | EXIT |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2023 vs prior quarter
Q3 2023
0
Increased
+0 shares0
New Positions
first time holders1
Decreased
−374.8K shares49
Sold Out
fully exitedNet shares change (top 50)
374.8K
+0 / −374.8K
Net new holders
-50
0 new / 49 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
PRDS insider trading · insider activity
Source: SEC Form 4
4
Buy transactions
42
Sell transactions
0.10
Buy/Sell ratio
$24M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Tananbaum James B. President and CEO | Aug 31, 2023 | J-Other | 1,000 | $0.00 | $0.1 | 1.0K | Form 4 ↗ |
Tananbaum James B. President and CEO | Aug 31, 2023 | D-Return | 37,500 | $1.87 | $70.1K | 0 | Form 4 ↗ |
Tananbaum James B. President and CEO | Aug 31, 2023 | D-Return | 75,000 | $9.80 | $735.0K | 0 | Form 4 ↗ |
Tananbaum James B. President and CEO | Aug 31, 2023 | D-Return | 16,813,146 | $0.00 | $1.7K | 0 | Form 4 ↗ |
Tananbaum James B. President and CEO | Aug 31, 2023 | D-Return | 37,500 | $5.21 | $195.4K | 0 | Form 4 ↗ |
WIGGANS THOMAS G Chief Executive Officer | Aug 31, 2023 | U-Tender | 50,000 | $2.13 | $106.5K | 0 | Form 4 ↗ |
WIGGANS THOMAS G Chief Executive Officer | Aug 31, 2023 | D-Return | 562,500 | $2.08 | $1.17M | 0 | Form 4 ↗ |
WIGGANS THOMAS G Chief Executive Officer | Aug 31, 2023 | D-Return | 985,000 | $6.36 | $6.26M | 0 | Form 4 ↗ |
WIGGANS THOMAS G Chief Executive Officer | Aug 31, 2023 | D-Return | 450,000 | $2.98 | $1.34M | 0 | Form 4 ↗ |
Varney Michael David director | Aug 31, 2023 | D-Return | 37,500 | $1.87 | $70.1K | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Pardes Biosciences, Inc. (PRDS) is primarily owned by institutional investors, who hold approximately 0.1% of total shares outstanding. Company insiders own approximately 77.33%, while retail and public investors account for the remaining 22.62%.
The largest institutional shareholder of Pardes Biosciences, Inc. is BARCLAYS PLC, holding approximately 31,037 shares — equal to 5.15% of outstanding shares — as of September 30, 2023.
A total of 1 institutional investors currently hold PRDS stock, with a combined institutional value of approximately $66,730 as of the most recent 13F filing period.
Frequently asked questions
PRDS ownershipPardes Biosciences, Inc. (PRDS) is primarily owned by institutional investors, who hold approximately 0.1% of shares. The largest shareholder is BARCLAYS PLC with a 5.15% stake. Company insiders hold 77.33%. Data sourced from SEC Form 13F as of September 30, 2023.